Banner 1

ESMO 2016: data information intelligence presents granular results about the current and future adoption of NGS in European clinical diagnostics

Data information intelligence will present new data on the adoption of next generation sequencing (NGS) in molecular oncology at ESMO 2016 in Copenhagen. The annual congress of the European Society for Medical Oncology allows medical oncologists and other professionals in this field to learn about the latest research as well as to share best practices. As the popular congress builds bridges between researchers and clinicians, one of the most important topics is targeted therapy, as facilitated by NGS.

Using and applying NGS methods in diagnostic laboratories changes how cancers can be identified and treated and improves patients' outcomes for the future. These new methods can reveal more actionable genomic mutations than standard diagnostic methods. But to what extent have NGS systems been adopted at present and what does the future look like?

In 2015 and 2016, data information intelligence surveyed more than 2000 laboratories on NGS adoption in clinical laboratories in general and molecular methods for BRCA, BRAF, RAS and EGFR and others in Western Europe in particular.

The integration of NGS into clinical molecular diagnostic laboratories has been increasing, but it varies by country. While Germany has the lowest adoption of NGS in molecular oncology diagnostic laboratories, the United Kingdom has the highest NGS adoption rate and Italy is positioned in the middle. Overall, 17% of all molecular oncology diagnostic laboratories in Europe have NGS installations and 21% of those not currently running NGS are planning to acquire it within the next five years. The results also showed clear preferences in the different NGS systems being used.

The popularization of smaller and easier to use NGS systems will help to grow clinical NGS deployment in order to gain a deeper and more accurate understanding of the molecular underpinnings of individual tumors. Regardless, increased automation, more panels and easier result reporting are necessary for increasing the implementation of NGS in oncology testing. Detailed results of current and future adoption of NGS in European molecular oncology diagnostics will be presented during a poster session on October 10th in Hall E at ESMO 2016. Senior Consultant Mark Whitten is available to answer questions between 1 and 2pm.